Total Raised

$156.13M

Investors Count

10

Deal Terms

4

Funding, Valuation & Revenue

34 Fundings

Exagen has raised $156.13M over 34 rounds.

Exagen's latest funding round was a PIPE for $60.1M on March 21, 2021.

Exagen's valuation in September 2019 was $157.27M.

Exagen's 2020 revenue was $41.98M. Exagen's most recent revenue is from 2020.

Sign up for a free demo to see revenue data from 2021, 2020 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

3/21/2021

PIPE

$60.1M

Undisclosed Investors

$XXM

$X.XXB

((X.XXx))

FY XXXX

2

9/19/2019

IPO

$50.4M

$157.27M

$X.XXB

((X.XXx))

FY XXXX

1

2/1/2019

Series G

$6.59M

$XXM

$41.98M

FY 2020

1

9/11/2017

Debt - XVII

$XXM

$XXM

0

FY undefined

10

5/18/2017

Unattributed

$XXM

$XXM

0

FY undefined

10

Date

3/21/2021

9/19/2019

2/1/2019

9/11/2017

5/18/2017

Round

PIPE

IPO

Series G

Debt - XVII

Unattributed

Amount

$60.1M

$50.4M

$6.59M

$XXM

$XXM

Investors

Undisclosed Investors

Valuation

$XXM

$157.27M

$XXM

$XXM

$XXM

Revenue

$X.XXB

((X.XXx))

FY XXXX

$X.XXB

((X.XXx))

FY XXXX

$41.98M

FY 2020

0

FY undefined

0

FY undefined

Sources

2

1

1

10

10

Start free trial
New call-to-action

Exagen Deal Terms

4 Deal Terms

Exagen's deal structure is available for 4 funding rounds, including their IPO from September 19, 2019.

Round

IPO

Series B - II

Series B

Series A

Funding Date

$XXM

$XXM

$XXM

$XXM

Pre-Money Valuation

$XXM

$XXM

Post-Money Valuation

$XXM

$XXM

Amount Raised

$XXM

$XXM

$XXM

$XXM

Shares Authorized

Issuance Price

$XXM

Dividend Rate

$XXM

Liquidation Preferences

$XXM

Liquidation Price

Participation

Conversion Price

Anti Dilution

$XXM

General Voting

$XXM

$XXM

$XXM

$XXM

Board Voting

$XXM

$XXM

$XXM

$XXM

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series B - II

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

$XXM

Series B

$XXM

$XXM

$XXM

$XXM

Series A

$XXM

$XXM

$XXM

$XXM

Exagen Investors

10 Investors

Exagen has 10 investors. Tullis Health Investors invested in Exagen's Series G funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/5/2004

2/1/2019

12
Series A, Series B (2005), Series B - II (2006), Debt (2007), Debt - II (2008), Series C (2009), Series C - II (2011), Series C - III (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series G (2019)

Thomas Dickerson

Private Equity

Connecticut

5/6/2009

2/1/2019

11
Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019)

Investment Bank

New Mexico

5/6/2009

2/1/2019

11
Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019)

Venture Capital

New Mexico

00/00/0000

00/00/0000

Innovatus Capital Partners

Subscribe to see more

Debt & Specialty Finance

New York

00/00/0000

00/00/0000

CRG

Subscribe to see more

Debt & Specialty Finance

Texas

First funding

1/5/2004

5/6/2009

5/6/2009

00/00/0000

00/00/0000

Last Funding

2/1/2019

2/1/2019

2/1/2019

00/00/0000

00/00/0000

Investor

Innovatus Capital Partners

CRG

Rounds

12
Series A, Series B (2005), Series B - II (2006), Debt (2007), Debt - II (2008), Series C (2009), Series C - II (2011), Series C - III (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series G (2019)
11
Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019)
11
Series C, Series C - II (2011), Series C - III (2011), Series C - IV (2011), Debt - III (2011), Series D (2011), Series E (2012), Unattributed VC (2012), Series E - II (2013), Series F (2016), Series G (2019)

Subscribe to see more

Subscribe to see more

Board Seats

Thomas Dickerson

Type

Private Equity

Investment Bank

Venture Capital

Debt & Specialty Finance

Debt & Specialty Finance

Location

Connecticut

New Mexico

New Mexico

New York

Texas

Exagen Acquisitions

1 Acquisition

Exagen acquired 1 company. Their latest acquisition was Cypress Bioscience - Diagnostic Business on October 08, 2010.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/8/2010

$XXM

Acquired Unit

1

Date

10/8/2010

Investment Stage

Companies

Valuation

$XXM

Total Funding

Note

Acquired Unit

Sources

1

New call-to-action

Compare Exagen to Competitors

NeoDiagnostix Logo
NeoDiagnostix

NeoDiagnostix is a cancer diagnostics company with a focus on women's health, specifically in the domain of cervical cancer detection. The company's main offering is the Cervical DNA Dtex Test, which identifies irreversible DNA damage to cervical cells as an indicator of potential cancer. This diagnostic tool is primarily utilized by healthcare providers in the medical sector. It is based in Rockville, Maryland.

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

P
Prognomix

Predict to Prevent  Prognomixs vision is the development of personalized medicine for the early detection of susceptibilities to diseases their complications and individual therapeutic responsiveness using genomic signatures Their initial focus is the development  of  presymptomatic diagnostic tools of diabetic complications based on genomic signatures aimed at individualized targeted prevention

CivaTech Oncology Logo
CivaTech Oncology

CivaTech Oncology focuses on localized radiation therapy within the medical devices sector. The company specializes in developing polymer-based low dose rate brachytherapy devices designed to treat various stages of cancer by providing targeted radiation therapy. Its products, including CivaSheet, CivaString, and CivaDerm, offer customizable solutions for radiation oncologists to deliver individualized treatment, aiming to reduce procedure time, ensure homogeneous dose distribution, and minimize patient trauma. It was founded in 2006 and is based in Durham, North Carolina.

CS-Keys Logo
CS-Keys

CS-Keys is a digital marketplace for the sale of keys for the games CS:GO and Team Fortress 2. The company offers a platform for purchasing and selling virtual item keys, allowing transactions through Steam profiles and accepting payments via the Privat24 system. CS-Keys provides a service for trading these in-game keys. It was founded in 2006 and is based in Indianapolis, Indiana.

Akonni Biosystems Logo
Akonni Biosystems

Akonni Biosystems operates in the molecular diagnostics field within the biotechnology sector. The company provides nucleic acid purification kits that use pipette-tip technology for DNA and RNA extraction, applicable for whole genome sequencing, next-generation sequencing, and polymerase chain reaction. Akonni Biosystems serves the healthcare and research sectors with its genetic testing devices and sample preparation solutions. It was founded in 2003 and is based in Fredrick, Maryland.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.